Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors
Latest Information Update: 18 Aug 2022
At a glance
- Drugs Lurbinectedin (Primary) ; Paclitaxel (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Gynaecological cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors PharmaMar
- 10 Aug 2022 Results published in the Investigational New Drugs
- 19 Sep 2019 Results published in the Luye Pharma Group Media Release.
- 19 Sep 2019 According to an Luye Pharma Group media release, clinical data from this study were presented at the World Conference on Lung Cancer.